金融界4月2日消息， 康希诺披露投资者关系活动记录表显示，公司流脑结合疫苗MCV4曼海欣®在2024年实现了销售收入7.94亿元，同比增长41%。该疫苗为中国市场唯一的脑膜炎球菌四价结合疫苗产品，公司通过学术营销和市场教育加强品牌建设，提升了市场接受度。此外，MCV4已于2024年底在印度尼西亚获得注册证书，预计2025年启动上市销售，并正在推进该产品在更多国家和地区的准入工作。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.